The DEA holds final authority on rescheduling marijuana from Schedule I to Schedule III after HHS's 2023 scientific recommendation affirming accepted medical use and lower abuse potential than heroin or LSD. President Trump's December 2025 executive order directed the Attorney General to expedite rulemaking, yet the process remains stalled four months later amid leadership changes, including new DEA Administrator Terry Cole. Rep. Steve Cohen's March 27 letter pressed Attorney General Pam Bondi and Cole for a timeline update, citing sidelined Biden-era progress and questioning plans without an administrative law judge hearing. No public response has emerged, fueling trader uncertainty ahead of potential summer hearings, final rules, or midterm pressures in November 2026.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$310,083 Wol.
Mar 31, 2026
June 30
13%
December 31
37%
$310,083 Wol.
June 30
$19,514 Wol.
13%
December 31
$25,686 Wol.
37%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA holds final authority on rescheduling marijuana from Schedule I to Schedule III after HHS's 2023 scientific recommendation affirming accepted medical use and lower abuse potential than heroin or LSD. President Trump's December 2025 executive order directed the Attorney General to expedite rulemaking, yet the process remains stalled four months later amid leadership changes, including new DEA Administrator Terry Cole. Rep. Steve Cohen's March 27 letter pressed Attorney General Pam Bondi and Cole for a timeline update, citing sidelined Biden-era progress and questioning plans without an administrative law judge hearing. No public response has emerged, fueling trader uncertainty ahead of potential summer hearings, final rules, or midterm pressures in November 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Rynek otwarty: Feb 7, 2026, 5:04 PM ET
Wolumen
$310,083Data zakończenia
Mar 31, 2026Rynek otwarty
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA holds final authority on rescheduling marijuana from Schedule I to Schedule III after HHS's 2023 scientific recommendation affirming accepted medical use and lower abuse potential than heroin or LSD. President Trump's December 2025 executive order directed the Attorney General to expedite rulemaking, yet the process remains stalled four months later amid leadership changes, including new DEA Administrator Terry Cole. Rep. Steve Cohen's March 27 letter pressed Attorney General Pam Bondi and Cole for a timeline update, citing sidelined Biden-era progress and questioning plans without an administrative law judge hearing. No public response has emerged, fueling trader uncertainty ahead of potential summer hearings, final rules, or midterm pressures in November 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Wolumen
$310,083Data zakończenia
Mar 31, 2026Rynek otwarty
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The DEA holds final authority on rescheduling marijuana from Schedule I to Schedule III after HHS's 2023 scientific recommendation affirming accepted medical use and lower abuse potential than heroin or LSD. President Trump's December 2025 executive order directed the Attorney General to expedite rulemaking, yet the process remains stalled four months later amid leadership changes, including new DEA Administrator Terry Cole. Rep. Steve Cohen's March 27 letter pressed Attorney General Pam Bondi and Cole for a timeline update, citing sidelined Biden-era progress and questioning plans without an administrative law judge hearing. No public response has emerged, fueling trader uncertainty ahead of potential summer hearings, final rules, or midterm pressures in November 2026.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania